Effect of an Innovative BIO Formula Intake on Infant Growth and Tolerance From 0 to 6 Months (TRUEGREEN)
Evaluation of an Innovative BIO Formula Based on a New Whey Extraction Process on the Growth and Tolerance of Infants From 0 to 6 Months.
From birth to 5 months, milk is the essential and unique food of the newborn. The French National Nutrition Program (PNNS) recommends exclusive breastfeeding "up to 6 months and at least 4 months for a healthy benefit". However, only 36% of infants 0-6 months of age are exclusively breastfed worldwide. Some mothers choose to give infant formula to their baby in the first few months of life. This decision may be a personal choice or be imposed by pathophysiological situations.
The nutritional requirements of the infant are specific, which implies adequate nutrition. Infant formulas and follow-up formulas are therefore complex products, specially developed for a group of vulnerable consumers. In fact, the compositional and information requirements for infant formula are highly regulated.
This study, defined as a pilot study, proposes to evaluate the innovative "TrueGreen" BIO infant formula based on a new whey extraction method on the growth and tolerance of infants from 0 to 6 months compared to the conventional BIO infant formula. As no growth and tolerance data are currently available for this new TrueGreen BIO formula, this study aims to determine them.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Nord
-
Lille, Nord, França, 59019
- NutrInvest - Institut Pasteur de Lille
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- 0 to 3 weeks
- Child followed by a general practitioner or pediatrician
- Informed consent form signed by the legal representatives of the subject
- Commitment of legal representatives to follow the constraints generated by the study
- Insured
Exclusion Criteria:
- Infant born prematurely before 37 weeks of amenorrhea
- Child allergic to cow's milk proteins
- Pathological pregnancy (hypertension, infection, gestational diabetes, etc.);
- Chronic or acute illness (metabolic or neuromuscular diseases, epilepsy, asthma, diabetes, digestive, renal, cardiac or haematological diseases);
- Incapacity for the legal representative(s) to understand or adhere to the protocol
- Subject involved in another clinical study or in an exclusion period from another study
- Legal representatives deprived of liberty
- Legal representatives in a position to judicial protection
- Weight of the subject according to age and sex, not included between the 3rd and the 97th percentile of the WHO Child Growth Standards
- Subject height according to age and sex, not between the 3rd and the 97th percentile of the WHO Child Growth Standards
- BMI of the subject according to age and sex, not included between the 3rd and the 97th percentile of the WHO Child Growth Standards
- Head circumference of the subject according to age and sex, not included between the 3rd and the 97th percentile of the WHO (World Health Organization) Child Growth Standards
- The investigator considers that the state of health or the concomitant treatments are not compatible with the good progress of the clinical study.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Outro
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador de Placebo: Breast milk
group receiving breastfeeding
|
Infants were breastfed during 3 months minimum.
Data on growth and tolerance were collected.
10 out of 40 infants take a blood test to metabolome analysis
|
|
Comparador Ativo: infant formula conventional BIO
infant formula with conventional whey BIO
|
Infant were fed during 6 months with a conventional BIO infant formula.
Data on growth and tolerance were collected.
10 out of 40 infants take a blood test to metabolome analysis
|
|
Comparador Ativo: infant formula BIO TrueGreen
infant formula with whey BIO TrueGreen
|
Infant were fed during 6 months with the TrueGreen BIO infant formula.
Data on growth and tolerance were collected.
10 out of 40 infants take a blood test to metabolome analysis
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Evolution of growth of infants
Prazo: from 0 to 6 months
|
Weight in kilograms
|
from 0 to 6 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Height evolution of infants
Prazo: from 0 to 6 months
|
data in centimeters
|
from 0 to 6 months
|
|
BMI evolution of infants
Prazo: from 0 to 6 months
|
data in kg/m²
|
from 0 to 6 months
|
|
Head circumference evolution of infants
Prazo: from 0 to 6 months
|
data in centimeters
|
from 0 to 6 months
|
|
Number of colic per day
Prazo: from 0 to 6 months
|
Evaluation during 3 consecutives days every month.
|
from 0 to 6 months
|
|
Consistency of stool
Prazo: from 0 to 6 months
|
Evaluation during 3 consecutive days every month via Bristol scale. According to the bristol scale, seven types of stool are considered: Type 1: Separate hard lumps, like nuts (hard to pass) Type 2: Sausage-shaped, but lumpy Type 3: Like a sausage but with cracks on its surface Type 4: Like a sausage or snake, smooth and soft Type 5: Soft blobs with clear cut edges (easy to pass) Type 6: Fluffy pieces with ragged edges, a mushy stool Type 7: Watery, no solid pieces, entirely liquid The mean of stool type during 3 days is considered. |
from 0 to 6 months
|
|
Number of regurgitation
Prazo: from 0 to 6 months
|
Evaluation during 3 consecutive days every month via Vandenplas scale. According to the Vandenplas scale, seven score are considered: 0 0-2 episodes/day
The mean of score during 3 days is considered. |
from 0 to 6 months
|
|
Number of wake up per night
Prazo: from 0 to 6 months
|
Evaluation during 3 consecutive days every month.
|
from 0 to 6 months
|
|
Total sleep time per day
Prazo: from 0 to 6 months
|
Time in hours.
Evaluation during 3 consecutive days every month.
|
from 0 to 6 months
|
|
Plasma amino acid profile
Prazo: between 3rd and 4th month
|
Methods : Liquid Chromatography and Tandem Mass Spectrometry (LC / MS / MS) List of amino acids : Taurine, Aspartic acid, Threonine, Serine, Asparagine, Glutamine acid, Glutamine, Glycine, Alanine, Citrulline, Valine, Cystine, Methionine, Isoleucine, Leucine, Tyrosine, Phenylalanine, Beta aminoisobutyric acid, Ornithine, 1-Methyl-Histidine, Histidine, Lysine, 3-methyl-Histidine, Arginine, Hydroxyproline, Proline
|
between 3rd and 4th month
|
|
Metabolomic analysis from plasma and urine samples
Prazo: between 3rd and 4th month
|
Non-targeted analysis : evaluation of all small molecules in biological system, such as amino acids, sugars, alcohols, sugar phosphates, amines, fatty acids, polar lipids, hormones and vitamins, as well as specialized metabolites, such as phenolic compounds, flavonoids, monoterpenes, sesquiterpenes, polyketides, alkaloids, including xenobiotics. Methods : Liquid Chromatography and Mass Spectrometry (LC / MS) |
between 3rd and 4th month
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Outros números de identificação do estudo
- 2018-A00732-53
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Desenvolvimento infantil
-
RenJi HospitalConcluídoRazão Contagem de Plaquetas/Diâmetro do Baço | Classificação Child-PughChina
-
Stanford UniversityNational Cancer Institute (NCI)RescindidoCarcinoma hepatocelular recorrente | Child-Pugh Classe A | Child-Pugh Classe BEstados Unidos, Japão
-
Boehringer IngelheimNão está mais disponívelDoenças pulmonares intersticiais (em populações pediátricas) | Doença pulmonar intersticial infantil (chILD)
-
Ohio State University Comprehensive Cancer CenterVarian Medical SystemsConcluídoChild-Pugh Classe A | Carcinoma hepatocelular estágio IIIA | Carcinoma hepatocelular estágio IIIB | Carcinoma hepatocelular estágio IIIC | Carcinoma Hepatocelular Estágio IVA | Carcinoma hepatocelular estágio IVB | Child-Pugh Classe BEstados Unidos
-
Centre Hospitalier Universitaire DijonConcluídoCarcinoma Hepatocelular Child-Pugh AFrança
-
Roswell Park Cancer InstituteMerck Sharp & Dohme LLCAtivo, não recrutandoCarcinoma Hepatocelular Adulto Avançado | Child-Pugh Classe A | Carcinoma hepatocelular estágio III | Carcinoma hepatocelular estágio IIIA | Carcinoma hepatocelular estágio IIIB | Carcinoma hepatocelular estágio IIIC | Carcinoma hepatocelular estágio IV | Carcinoma Hepatocelular Estágio IVA | Carcinoma...Estados Unidos
-
AstraZenecaRescindidoCâncer de intestino | Malignidades Sólidas Avançadas | Tumor Sólido | Child-Pugh A a B7 Carcinoma Hepatocelular Avançado | NSCLC mutante EGFR e/ou ROS | Carcinoma Metástase PulmonarRepublica da Coréia
Ensaios clínicos em Breastfeeding
-
University of Ontario Institute of TechnologyDurham Region Health DepartmentDesconhecido